Polypeptide N-acetylgalactosaminyltransferase-6 expression independently predicts poor overall survival in patients with lung adenocarcinoma after curative resection
PDF | HTML | Supplementary Files | How to cite
Metrics: PDF 1837 views | HTML 2028 views | ?
Zhi Li1,2, Sohsuke Yamada2,9,10, Ying Wu1, Ke-Yong Wang3, Yun-Peng Liu1, Hidetaka Uramoto4,7, Kimitoshi Kohno5,8, Yasuyuki Sasaguri2,6
1Department of Medical Oncology, The First Hospital, China Medical University, Shenyang, China
2Department of Pathology and Cell Biology, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
3Bio-information Research Center, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
4Second Department of Surgery, School of Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
5The President Laboratory, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan
6Laboratory of Pathology, Fukuoka Wajiro Hospital, Fukuoka, Japan
7Division of Thoracic Surgery, Saitama Cancer Center, Saitama, Japan
8Asahi-Matsumoto Hospital, Kitakyushu, Japan
9Institute of Pathology, Medical University of Graz, Graz, Austria
10Department of Pathology, Field of Oncology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
Yun-Peng Liu, email: [email protected]
Sohsuke Yamada, email: [email protected]
Keywords: GalNAc-T6, glycosylation, lung adenocarcinoma, prognosis, overall survival
Received: March 02, 2016 Accepted: May 04, 2016 Published: June 03, 2016
Background: Polypeptide N-acetylgalactosaminyltransferases (GalNAc-Ts) are important glycosyltransferases in cancer, but the clinical role of its individual isoforms is unclear. We investigated the clinical significance and survival relevance of one isoform, GalNAc-T6 in lung adenocarcinoma after curative resection.
Results: GalNAc-T6 was identified in 27.8% (55/198) of patients, and statistically indicated advanced TNM stage (P = 0.069). Multivariate analysis showed GalNAc-T6 to be an independent predictor for reduced overall survival of patients (P = 0.027), and the result was confirmed with bootstraping techniques, and on line "Kaplan-Meier Plotter" and "SurvExpress" database analysis, respectively. Moreover, ROC curve demonstrated that GalNAc-T6 expression significantly improved the accuracy of survival prediction.
Methods: With 198 paraffin-embedded tumor samples from lung adenocarcinoma patients, GalNAc-T6 expression was immunohistochemically assessed for the association with clinicopathological parameters. The prognostic significance was evaluated by Cox proportional hazards regression analysis with 1000 bootstraping. "Kaplan-Meier Plotter", "SurvExpress" database analysis, and receiver-operating characteristic (ROC) curve were performed to provide further validation.
Conclusions: GalNAc-T6 expression correlated significantly with advanced TNM stage, and independently predicted worse OS for lung adenocarcinoma.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.